147 related articles for article (PubMed ID: 34280441)
21. A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection.
Cover J; Namagembe A; Tumusiime J; Lim J; Drake JK; Mbonye AK
Contraception; 2017 Mar; 95(3):306-311. PubMed ID: 27789309
[TBL] [Abstract][Full Text] [Related]
22. Acceptability of the distribution of DMPA-SC by community health workers among acceptors in the rural province of Lualaba in the Democratic Republic of the Congo: a pilot study.
Mwembo A; Emel R; Koba T; Sankoko JB; Ngay A; Gay R; Bertrand JT
Contraception; 2018 Nov; 98(5):454-459. PubMed ID: 30118683
[TBL] [Abstract][Full Text] [Related]
23. Costs of administering injectable contraceptives through health workers and self-injection: evidence from Burkina Faso, Uganda, and Senegal.
Di Giorgio L; Mvundura M; Tumusiime J; Namagembe A; Ba A; Belemsaga-Yugbare D; Morozoff C; Brouwer E; Ndour M; Drake JK
Contraception; 2018 Nov; 98(5):389-395. PubMed ID: 29859148
[TBL] [Abstract][Full Text] [Related]
24. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
Lancet Glob Health; 2018 May; 6(5):e568-e578. PubMed ID: 29526707
[TBL] [Abstract][Full Text] [Related]
25. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
[TBL] [Abstract][Full Text] [Related]
26. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.
Cameron ST; Glasier A; Johnstone A
Contraception; 2012 May; 85(5):458-64. PubMed ID: 22079602
[TBL] [Abstract][Full Text] [Related]
27. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.
Liu J; Shen J; Diamond-Smith N
Contraception; 2018 Nov; 98(5):430-437. PubMed ID: 29733817
[TBL] [Abstract][Full Text] [Related]
28. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.
Beasley A; White KO; Cremers S; Westhoff C
Contraception; 2014 May; 89(5):352-6. PubMed ID: 24656555
[TBL] [Abstract][Full Text] [Related]
29. Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.
Williams RL; Hensel DJ; Fortenberry JD
Contraception; 2013 Sep; 88(3):401-7. PubMed ID: 23294549
[TBL] [Abstract][Full Text] [Related]
30. Acceptability of the community-level provision of Sayana® Press by medical and nursing students in Kinshasa, Democratic Republic of the Congo.
Bertrand JT; Makani PB; Hernandez J; Akilimali P; Mukengeshayi B; Babazadeh S; Binanga A
Contraception; 2017 Sep; 96(3):211-215. PubMed ID: 28647500
[TBL] [Abstract][Full Text] [Related]
31. Designing a global monitoring system for pilot introduction of a new contraceptive technology, subcutaneous DMPA (DMPA-SC).
Stout A; Wood S; Namagembe A; Kaboré A; Siddo D; Ndione I
Eval Program Plann; 2018 Jun; 68():185-193. PubMed ID: 29609057
[TBL] [Abstract][Full Text] [Related]
32. Factors Affecting Continued Use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): A Secondary Analysis of a 1-Year Randomized Trial in Malawi.
Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Santo LD; Ngwira B
Glob Health Sci Pract; 2019 Mar; 7(1):54-65. PubMed ID: 30894394
[TBL] [Abstract][Full Text] [Related]
33. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [
